Page 116 - Socially-responsible-restructuring-Effective-strategies-for-supporting-redundant-workers
P. 116

Socially responsible restructuring
                                                          Effective strategies for supporting redundant workers




                     worldwide  with around 1 400 of these in the legacy Schering-Plough (Ireland)
                     organisation. Sites are currently based in Rathdrum, Co. Wicklow and Brinny, Co
                     Cork, in addition to the Bray plant.
                        At Bray the company currently employs around 240 people on site and this
                     number has been stable for some time. Around 100 employees are directly
                     involved  with  the production side and are generally experienced operatives,
                     some with specialist skills for this sector, but not  necessarily  with  any  formal
                     qualifications reflecting this work. Other staff are employed in support functions
                     such as quality, finance, engineering, supply chain, etc. and would have
                     qualifications and experience to match the needs of their particular jobs.
                        The plant is an important source of employment in the area and while  the
                     production staff tends to have fairly local  travel-to-work patterns, many other
                     employees travel from a much greater catchment area. Trade union membership
                     is  high  among  the  production and engineering staff, together accounting for
                     approximately 90 employees.

                     6.5.2.   Restructuring and job losses
                     The latest acquisition of the company by  Merck  Pharmaceuticals  follows  the
                     takeover in 2007 by a Dutch conglomerate (Organon Bio Sciences and Intervet)
                     and it was the decision of this company that precipitated the current restructuring
                     exercise. Following a review of the multinational’s production facilities worldwide,
                     the decision was taken to rationalise the number of plants. The Bray operation
                     (the only animal health manufacturing site of the three in Ireland) was earmarked
                     for closure. The need to bring about cost reductions was the principal motivation
                     behind this decision and the Bray plant was felt to need substantial investment to
                     upgrade its plant and machinery, more so than other plants in the group. As a
                     result, production will be phased out and switched to the  company’s  other
                     operations  in  Europe  –  including  Germany, Spain and France – indicating that
                     this  is  not  about  reducing  labour costs and was not a direct response to the
                     current economic recession.
                        The announcement of the closure was made in March 2009 and the current
                     timetable for the rundown of the plant sees ultimate closure by the  middle  of
                     2011.

                     6.5.3.   Restructuring practice and processes
                     The company has responded to the announcement of the planned closure with a
                     series of activities to inform staff and outline the timetable and types of help that
                     will be available. It has engaged the services of a private sector outplacement










                                                           110
   111   112   113   114   115   116   117   118   119   120   121